An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 6, Issue 4, 1996, Pages 241-250

  Olvera, Rene L ^a   Pliszka, Steven R ^a   Luh, Join ^a   Tatum, Ross ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYPERACTIVITY; MALE; NAUSEA; SCHOOL CHILD;

EID: 0030514010     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.1996.6.241     Document Type: Article

References (34)

1. Adler, LA, Resnick S, Kunz M, Devinsky O: Open label trial of venlafaxine (Effexor) in attention deficit disorder [abstract]. National Institute of Mental Health, Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Orlando (FL), May 1995
2. Barkley RA: Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York, The Guilford Press, 1990
3. Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M: Treatment of ADHD with fluoxetine: A preliminary trial. J Am Acad Child Adolesc Psychiatry 30:762-767, 1991
4. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS: A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777-784, 1989
5. Blouin AG, Perez EL, Blouin JH: Computerized administration of the Diagnostic Interview Schedule. Psychiatry Res 23:335-344, 1988
6. Bolden-Watson C, Richelson E: Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52:1023-1029, 1993
7. Conners CK: Continuous Performance Test Computer Program. Toronto, Multi-Health Systems, Inc. 1992
8. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Hearst E: A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 14:99-106, 1994
9. Derivan A, Aguiar L, Upton GV, Martin P, D'Amico D, Troy S, Ferguson J, Preskorn SA: Study of venlafaxine in children and adolescents with conduct disorder [abstract]. Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New Orleans (LA), 1995, p 128
10. Findling RL, Schwartz MA, Flannery DJ, Manos MJ: Venlafaxine in adults with attention deficit hyperactivity disorder: An open trial. J Clin Psychiatry 57:184-189, 1996
11. Gammon GD, Brown TE: Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 3:1-10, 1993
12. Goyette CH, Conners CK, Ulrich RF: Normative data on the Revised Connors Parent and Teacher Scales. J Abn Child Psychol 6:221-236, 1978
13. Guilé JM: Sertraline-induced activation during the treatment of an adolescent with major depression. J Child Adolesc Psychopharmacol 6:281-284, 1996
14. King RA, Riddle MA, Chappell P, Hardin MT, Anderson GM, Lombroso P, Scahill L: Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 30:179-186, 1991
15. Loeber R, Green SM, Lahey BB, Stouthamer-Loeber M: Differences and similarities between children, mothers, and teachers as informants on disruptive child behavior. J Abn Child Psychol 19:75-95, 1991
16. Mandoki M: Effects of venlafaxine in major depression in children and adolescents [letter]. Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New Orleans (LA), 1995, p 127
17. Mendels J, Johnston R, Mattes J, Riesenberg R: Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 29:169-174, 1993
18. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielson ST, Sigg EB: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493-4497, 1986
19. Physicians' Desk Reference, 50th Edition. Montvale (NJ), Medical Economics Company, 1996
20. Pleak RR, Gormly LJ: Effects of venlafaxine treatment for ADHD in a child [letter]. Am J Psychiatry 152:1099, 1995
21. Pliszka SR: Tricyclic antidepressants in the treatment of children with attention deficit disorder. J Am Acad Child Adolesc Psychiatry 26:127-132, 1987
22. Popper CW, Zimnitzky B: Sudden death putatively related to desipramine treatment in youth: A fifth case and a review of speculative mechanisms. J Child Adolesc Psychopharmacol 5:283-300, 1995
23. Reimherr FW, Hedges DW, Strong RE, Wender PH: An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder [abstract]. National Institute of Mental Health, Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Orlando (FL), 1995
24. Riddle MA, King RA, Hardin MT, Scahill L, Ort SI, Chappell P, Rasmusson A, Leckman JF: Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1:193-198, 1991b
25. ○: A review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 30:104-108, 1991a
26. Riddle MA, Geller B, Ryan N: Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 32:792-797, 1993
27. Saletu B, Grunberger J, Anderer P, Linzmayer L, Semlitsch HV, Magni G: Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Br J Clin Pharmacol 33:589-601, 1992
28. Schweizer E, Feighner J, Mandos LA, Rickels K: Comparison of venlafaxine and imipramine in the acute treatment of depression in outpatients. J Clin Psychiatry 55:104-108, 1994
29. Semlitsch HV, Anderer P, Saletu B, Binder GA, Decker KA: Acute effects of the novel antidepressant venlafaxine on cognitive event-related potentials (P300), eye blink rate and mood in healthy subjects. Intl Clin Psychopharmacol 8:155-166, 1993
30. Schwab-Stone ME, Shaffer D, Dulcan MK, Jensen PS, Fisher P, Bird HR, Goodman SH, Lahey BB, Lichtman JH, Canino G, Rubio-Stipec M, Rae DS: Criterion validity of the NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC 2.3). J Am Acad Child Adolesc Psychiatry 35:878-888, 1996
31. Shaffer D, Fisher P, Dulcan MK, Davies M, Piacentini J, Schwab-Stone ME, Lahey BB, Bourdon K, Jensen PS, Bird HR, Canino G, Regier DA: The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC 2.3): Description, acceptability, prevalence rates, and performance in the MECA Study. J Am Acad Child Adolesc Psychiatry 35:865-877, 1996
32. Tierney E, Joshi PT, Llinas JF, Rosenberg LA, Riddle MA: Sertraline for depression in children and adolescents: Preliminary clinical experience. J Child Adolesc Psychopharmacol 5:13-27, 1995
33. Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T: Nortriptyline in the treatment of ADHD: A chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 32:343-349, 1993
34. Zametkin AJ, Rapoport JL: Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years? J Am Acad Child Adolesc Psychiatry 26:676-686, 1987